Phase II trial of thalidomide for patients with advanced renal cell carcinoma

Journal of Clinical Oncology

Volumn 20, Issue 1, 2002, Pages 302-306

  Motzer, Robert J ^a   Berg, William ^a   Ginsberg, Michelle ^a   Russo, Paul ^a   Vuky, Jacqueline ^a   Yu, R Richard ^a   Bacik, Jennifer ^a   Mazumdar, Madhu ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; THALIDOMIDE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BRADYCARDIA; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG RESPONSE; DYSPNEA; FEMALE; HUMAN; KIDNEY CARCINOMA; MALE; NEPHRECTOMY; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN TOXICITY;

ADULT; AGED; ANGIOGENESIS INHIBITORS; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; SURVIVAL RATE; THALIDOMIDE;

EID: 0036139999     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.20.1.302     Document Type: Article

References (20)

1. Renal-cell carcinoma
2. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma
3. Renal cell carcinoma
4. Advances in angiogenesis research: Relevance to urological oncology
5. Thalidomide is an inhibitor of angiogenesis
6. Continuous low-dose thalidomide: A phase II study in advanced melanoma, renal cell, ovarian and breast cancer
7. Thalidomide for recurrent renal cell cancer in a 40-year-old man
8. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes
9. The immunosuppressive drug thalidomide induces T helper cell type 2 (TH2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures
10. Antitumor activity of thalidomide in refractory multiple myeloma
11. Reporting results of cancer treatment
12. Thalidomide treatment of metastatic renal cell carcinoma
13. Phase II study of thalidomide for patients with metastatic renal cell carcinoma progressing after interleukin-2-based therapy
14. Phase II trial of thalidomide in renal cell carcinoma
15. Phase II study of thalidomide in advanced refractory metastatic renal cell carcinoma: A single institution experience
16. Risk stratification in advanced renal cell carcinoma: A single-institution study of 237 patients
17. Clinical trial designs for cytostatic agents: Are new approaches needed?
18. Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal cell carcinoma
19. Systemic therapy for renal cell carcinoma
20. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy